08/25/2026
Our last post shared one of the biggest lessons from the research:
Timing matters. ⏱️
Now comes the next step.
The researchers have taken that lesson into the lab and made a bold decision — they’re treating the mice much earlier, during the newborn period.
Why?
Because if Mucolipidosis α/β begins its earliest damage in the first days and weeks of life, waiting may mean waiting too long.
So the team is moving earlier, aiming to get ahead of the disease before its key features take hold.
It’s a harder approach.
It’s a bolder approach.
And we believe it’s the right direction.
Help us keep moving forward. 💛
www.curemucolipidosis.org